National agency fees: charges by national competent authorities
National agency fees are the charges each EU/EEA competent authority sets in national law for applications, variations, renewals and annual maintenance.
Nothing in Directive 2001/83/EC harmonises what national competent authorities charge. Each Member State sets its fees in national law or a fee ordinance, so the cost of the same procedure differs widely between, for example, Germany, France, Spain and the smaller markets. Fees exist for national applications, for acting as reference member state or concerned member state in a decentralised or mutual recognition procedure, for repeat-use procedures, for Type IA, IB and II variations, for grouped variations and worksharing, for renewals, for Article 61(3) notifications in some countries, for transfers and for scientific advice. Most authorities also charge an annual fee per authorisation, sometimes per strength or presentation, which continues for as long as the authorisation exists whether or not the product is marketed.
The structure matters as much as the amount. Some authorities charge per authorisation, some per procedure, and some reduce the fee when several products or strengths are filed together. Reference member state fees are higher than concerned member state fees because the RMS does the assessment. Several countries also levy taxes or contributions that are not fees in the formal sense, such as a percentage of sales to fund the authority or the health system, and these appear in the overall cost of a market even though they are not paid to regulatory affairs. Fees change with national budget cycles, usually at the start of a year, and are published by the authority, not by EMA.
What goes wrong: a decentralised procedure is costed with the RMS fee only, leaving out ten concerned member state fees and ten annual fees; annual fees keep running on dormant authorisations that should have been withdrawn; a repeat-use procedure is launched without checking that the target markets' fees justify the expected sales; the fee for a grouped variation is assumed to be one fee when the authority charges per change; and a transfer leaves the old holder paying annual fees until the national register is updated. Because the figures sit in dozens of national documents in as many languages, keeping them current is work in itself, and most companies discover a changed fee only when the invoice arrives.
Used in
When scoping a procedure, calculate national fees for every market in a procedure with the Regunaut fee calculator, which keeps each authority's schedule current.
Related terms
- EMA fees: charges under Regulation (EU) 2024/568EMA fees are the charges set by Regulation (EU) 2024/568 for applications, variations, pharmacovigilance and other EMA procedures, applying from 2025.
- DCP: decentralised procedureThe decentralised procedure (DCP) authorises a medicine in several EU/EEA Member States at once when it is not yet authorised in any of them.
- CMS: concerned member stateA concerned member state (CMS) is any EU/EEA Member State, other than the reference member state, where an applicant seeks authorisation via a DCP or MRP.
- RMS: reference member stateThe reference member state (RMS) is the EU/EEA Member State that leads the assessment in a decentralised or mutual recognition procedure.
- RUP: repeat-use procedureA repeat-use procedure (RUP) is a further mutual recognition wave that adds new concerned member states to a product already authorised by DCP or MRP.
Last updated